U.S. market Closed. Opens in 11 hours 37 minutes

ALGS | Aligos Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue15.53M13.91M4.36MN/AN/AN/A
Cost of Revenue3.07M3.67M104.15M3.33M2.30MN/A
Gross Profit12.46M10.23M-99.79M-3.33M-2.30MN/A
Operating Expenses99.89M111.49M132.68M97.83M54.04M13.66M
Selling, General & Admin26.85M26.41M28.53M17.94M10.01M3.21M
Research & Development73.04M85.08M104.15M79.89M44.04M10.46M
Other Operating ExpensesN/AN/AN/A-10.55M302.00K-435.00K
Operating Income-87.43M-97.58M-128.32M-97.83M-54.04M-13.66M
Other Expenses / Income543.00K1.64M132.00K-10.55M1.86M-435.00K
Before Tax Income-86.88M-95.94M-128.19M-108.38M-52.18M-13.93M
Income Tax Expenses795.00K106.00K143.00K161.00K85.00K-272.00K
Net Income-87.68M-96.05M-128.33M-108.54M-52.26M-13.93M
Interest ExpensesN/A1.64M132.00K10.55MN/AN/A
Basic Shares Outstanding64.26M42.70M39.86M34.18M21.93M21.17M
Diluted Shares Outstanding64.26M42.70M39.86M34.18M21.93M21.17M
EBITDA-84.36M-97.58M-128.32M-97.83M-51.74M-12.37M
EBITDA Margin-543.23%-701.66%-2,943.82%0.00%0.00%0.00%
EBIT-86.88M-94.30M-128.06M-97.83M-52.18M-14.21M
EBIT Margin-559.50%-678.08%-2,937.76%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙